Experimental Study on the Therapeutical Effect of Lang Qing A Ta on Hepatic Fibrosis

PENG Yun-ru; DING Yong-fang; LUO Yu-hui; HUANG Yi-ping

您当前的位置：

首页 >

文章列表页 >

Experimental Study on the Therapeutical Effect of Lang Qing A Ta on Hepatic Fibrosis

更新时间：2024-01-04

- Experimental Study on the Therapeutical Effect of Lang Qing A Ta on Hepatic Fibrosis
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 18, Issue 11, Pages: 189-194(2012)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC：
- Published：2012
- 稿件说明：
移动端阅览
PENG Yun-ru, DING Yong-fang, LUO Yu-hui, et al. Experimental Study on the Therapeutical Effect of Lang Qing A Ta on Hepatic Fibrosis[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(11): 189-194.
DOI：

PENG Yun-ru, DING Yong-fang, LUO Yu-hui, et al. Experimental Study on the Therapeutical Effect of Lang Qing A Ta on Hepatic Fibrosis[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(11): 189-194. DOI：

摘要

目的: 研究藏药郎庆阿塔对复合因素所致大鼠肝纤维化的治疗作用。方法: 清洁级Wistar大鼠90只采用复合因素(高脂低蛋白饲料喂养、含乙醇饮用水加皮下注射四氯化碳)制备大鼠肝纤维化模型

造模6周末随机处死12只造模大鼠

通过肝组织病理检查及血清肝功能指标来检查肝纤维化模型成功率。将模型大鼠随机分为模型对照组、阳性药复方鳖甲软肝片组(0.55 g·kg-1)、郎庆阿塔颗粒给药高、中、低剂量组(生药11.4

5.7

2.85 g·kg-1)

另设正常对照组。各组大鼠于分组后即日(第7周)开始ig给药

每日1次

连续ig给药7周。治疗结束后

检测血清中生化指标和肝纤维化指标

并取肝脏组织

测定肝脏组织中羟脯氨酸含量、超氧化物歧化酶(SOD)活力及丙二醛(MDA)水平

另取肝脏组织标本进行病理组织学检查。结果: 郎庆阿塔能明显降低肝纤维化大鼠增高的肝脏系数和肝组织中羟脯氨酸含量(P<0.05~P<0.01)

显著降低肝纤维化大鼠血清中异常升高的天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)、碱性磷酸酶(ALP) 、总胆红素(T-BIL)、透明质酸(HA)、层黏连蛋白(LN)、Ⅲ型前胶原氨端肽(PⅢNP)及Ⅳ型胶原(CⅣ)(P<0.05~P<0.01)

升高白蛋白(ALB)和A/G比值

能明显升高肝组织中SOD活力(P<0.05~P<0.01)、降低异常升高的MDA水平(P<0.05~P<0.01)

病理组织学检查结果表明郎庆阿塔高、中剂量对肝纤维化大鼠肝纤维组织增生、肝组织炎症活动度均有显著的改善作用(P<0.05~P<0.01)

并能显著降低肝组织中胶原纤维面积(P<0.05~P<0.01)。结论: 藏药郎庆阿塔具有明显的治疗肝纤维化作用。

Abstract

Objective: To study the therapeutical effect of Lang Qing A Ta (LQAT) on hepatic fibrosis induced by composite factors in rats. Method: The hepatic fibrosis model was induced by high fat and low protein feed combined with administration of ethyl alcohol and a subcutaneous injection of CCl 4in rats and the model rats were divided into five groups as model group

Fufang Biejia Ruangan table group and LQAT groups at three doses. The rats were orally treated with corresponding decoctions once a day for 7 weeks.The levels of biochemical indicators and hepatic fibrosis indicators in serum were detected

as well as the levels of hydroxyproline

superoxide dismutaso(SOD) and malondialdehyde(MDA) in liver. The histopathologic examination was proceeded to evaluate the pathological changes in livers. Result: LQAT decoction could remarkably decrease the liver coefficients and hydroxyproline contents of liver in hepatic fibrosis rats

decrease the levels of aspartate aminotransferase(AST)

alanine aminotransferase(ALT)

alkalinephosphatase(ALP)

total bilirubin(T-BIL)

hyaluronic acid(HA)

laminin(LN)

procollagen Ⅲ N-terminal peptide(PⅢNP)

collagen type Ⅳ(CⅣ) and increase the levels of albumin(ALB) and alburmin/globulin(A/G) in serum. Furthermore

LQAT decoction could obviously increase the activity of SOD and decrease the MDA levels in liver. The results of histopathologic examination showed that LQAT at high and medium doses could ameliorate the pathological changes such as fibroplasia and inflammation and decrease the area of collagen fiber in livers. Conclusion: LQAT decoction has significant therapeutical effects on hepatic fibrosis in rats.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Dendrobium officinale Polysaccharides in Reversing Hepatic Fibrosis in Rats via Notch Signaling Pathway and Ultrasound Evaluation

Efficacy of Tiaogan Huaxian Pills in Prevention and Treatment of Hepatic Fibrosis in Hepatitis B and Its Effect on Diffusion-weighted Imaging

Traditional Chinese Medicine Treats Hepatic Fibrosis via NF-κB Signaling Pathway： A Review

Traditional Chinese Medicine Against Liver Fibrosis Based on Autophagy： A Review

Analysis of Mechanism of Qinggan Jianpi Huoxue Prescription in Treatment of Hepatic Fibrosis Rats by Regulating M1/M2 Macrophages

Related Author

XU Ying

LUO Jina

YANG Liuqing

TIAN Qianqian

CHENG Jiamao

CHEN Haiyan

DAI Haiyang

HUANG Guye

Related Institution

School of Clinical Medicine，Dali University，Dali

The First Affiliated Hospital of Dali University，Dali

School of Basic Medical Sciences，Dali University，Dali

Dali Bai Autonomous Prefecture People's Hospital，Dali

Guangxi University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰